Lectin-like transcript 1 as a natural killer cell-mediated immunotherapeutic target for triple negative breast cancer and prostate cancer

Abstract

Breast and prostate cancer are the leading causes of death in females and males, respectively. Triple negative breast cancer (TNBC) does not express the estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2, resulting in limited treatment options. Androgen deprivation therapy is the standard care for prostate cancer patients; however, metastasis and recurrence are seen in androgen-independent prostate cancer. Both prostate and breast cancer show higher resistance after recurrence and metastasis, which increases the difficulty of treatment. Natural killer (NK) cells play a critical role during innate immunity and tumor recognition and elimination. NK cell function is determined by a delicate balance of inhibitory signals and activation signals received through cell surface receptors. Lectin-like transcript 1 (LLT1, CLEC2D, OCIL) is a ligand of NK cell inhibitory receptor NKRP1A (CD161). Several studies have that reported higher expression of LLT1 is associated with the development of various tumors. Our studies revealed that TNBC and prostate cancer cells express higher levels of LLT1. In the presence of a monoclonal antibody against LLT1, NK cell-mediated killing of TNBC and prostate cancer cells were greatly enhanced. This review highlights the potential that using monoclonal antibodies to block LLT1 - NKRP1A interactions could be an effective immunotherapeutic approach to treat triple negative breast cancer and prostate cancer.

Keywords

Natural killer cell / lectin-like transcript 1 / CLEC2D / CD161 / breast cancer / prostate cancer / immunotherapy

References

[1] Swoboda A.Immune checkpoint blockade for breast cancer..Cancer Treat Res2018;173:155-65 PMCID:PMC6061922

[2] Siegel RL,Jemal A.Cancer statistics, 2019..CA Cancer J Clin2019;69:7-34

[3] Bianchini G,Mayer IA,Gianni L.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease..Nat Rev Clin Oncol2016;13:674-90 PMCID:PMC5461122

[4] Schreiber RD,Smyth MJ.Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion..Science2011;331:1565-70

[5] Bayraktar S,Okuno S.Immunotherapy in breast cancer..J Carcinog2019;18:2 PMCID:PMC6540776

[6] Llibre A,Marafioti T,Partridge A.LLT1 and CD161 expression in human germinal centers promotes B cell activation and CXCR4 downregulation..J Immunol2016;196:2085-94 PMCID:PMC4760235

[7] Llibre A,Willberg CB.Multi-functional lectin-like transcript-1: a new player in human immune regulation..Immunol Lett2016;177:62-9

[8] Roth P,Wick W,Tatagiba M.Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1..Cancer Res2007;67:3540-4

[9] Marrufo AM,Chaudhary P,Vishwanatha JK.Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells..Am J Cancer Res2018;8:1050-63 PMCID:PMC6048397

[10] Heuck C.Multiple Myeloma.2018;New YorkSpringer

[11] Dai X,Bai Z.Breast cancer cell line classification and its relevance with breast tumor subtyping..J Cancer2017;8:3131-41 PMCID:PMC5665029

[12] Malorni L,De Angelis C,Rimawi MF.Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up..Breast Cancer Res Treat2012;136:795-804 PMCID:PMC3513514

[13] Cancer Genome Atlas NComprehensive molecular portraits of human breast tumours..Nature2012;490:61-70 PMCID:PMC3465532

[14] Banerji S,Rangel-Escareno C,Carter SL.Sequence analysis of mutations and translocations across breast cancer subtypes..Nature2012;486:405-9 PMCID:PMC4148686

[15] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[16] Ding SL,Yu JC,Chen BF.Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade..Br J Cancer2004;90:1995-2001 PMCID:PMC2409464

[17] Shah SP,Goya R,Ha G.The clonal and mutational evolution spectrum of primary triple-negative breast cancers..Nature2012;486:395-9 PMCID:PMC3863681

[18] Brown SD,Gibb EA,Spinelli JJ.Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival..Genome Res2014;24:743-50 PMCID:PMC4009604

[19] Zelefsky MJ,Cronin AM,Zhang Z.Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix..J Clin Oncol2010;28:1508-13 PMCID:PMC3731893

[20] D’Amico AV,Renshaw AA,Kantoff PW.Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial..JAMA2008;299:289-95

[21] Zietman AL,Slater JD,Efstathiou JA.Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09..J Clin Oncol2010;28:1106-11 PMCID:PMC2834463

[22] Zhou Y,Jones JO.Androgens and androgen receptor signaling in prostate tumorigenesis..J Mol Endocrinol2015;54:R15-29

[23] Feldman BJ.The development of androgen-independent prostate cancer..Nat Rev Cancer2001;1:34-45

[24] Chandrasekar T,Gao AC.Mechanisms of resistance in castration-resistant prostate cancer (CRPC)..Transl Androl Urol2015;4:365-80 PMCID:PMC4708226

[25] Sullivan JL,Brewster FE.Deficient natural killer cell activity in x-linked lymphoproliferative syndrome..Science1980;210:543-5

[26] Roder JC,Klein M,Jett JR.A new immunodeficiency disorder in humans involving NK cells..Nature1980;284:553-5

[27] Talmadge JE,Prieur DJ.Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice..J Natl Cancer Inst1980;65:929-35

[28] Gorelik E,Okumura K,Herberman RB.Role of NK cells in the control of metastatic spread and growth of tumor cells in mice..Int J Cancer1982;30:107-12

[29] Moretta A,Vitale M,Cantoni C.Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis..Annu Rev Immunol2001;19:197-223

[30] Morvan MG.NK cells and cancer: you can teach innate cells new tricks..Nat Rev Cancer2016;16:7-19

[31] Thielens A,Romagne F.NK cell MHC class I specific receptors (KIR): from biology to clinical intervention..Curr Opin Immunol2012;24:239-45

[32] Chiossone L,Vienne M.Natural killer cells and other innate lymphoid cells in cancer..Nat Rev Immunol2018;18:671-88

[33] Sun JC.NK cell development, homeostasis and function: parallels with CD8(+) T cells..Nat Rev Immunol2011;11:645-57 PMCID:PMC4408539

[34] Lorenzo-Herrero S,Sordo-Bahamonde C,Vitale M.NK cell-based immunotherapy in cancer metastasis..Cancers (Basel)2018;11: PMCID:PMC6357056

[35] Kriegsman BA,Chen BJ,Brass AL.Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression..J Immunol2019;203:1999-2010 PMCID:PMC6761035

[36] Fang F,Tian Z.NK cell-based immunotherapy for cancer..Semin Immunol2017;31:37-54

[37] Boles KS,Bennett M,Mathew PA.2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes..Immunol Rev2001;181:234-49

[38] Kumaresan PR,Chuang SS,Mathew PA.CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function..Mol Immunol2002;39:1-8

[39] Tai YT,Song W,Li XF.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu..Blood2008;112:1329-37 PMCID:PMC2515112

[40] Malaer JD.CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma..Am J Cancer Res2017;7:1637-41 PMCID:PMC5574936

[41] Mathew SO,Powers SB,Mathew PA.Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction..Oncotarget2016;7:68650-61 PMCID:PMC5356580

[42] Hsu J,Marathe M,Bourgeois-Daigneault MC.Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade..J Clin Invest2018;128:4654-68 PMCID:PMC6159991

[43] Guillerey C,Smyth MJ.Targeting natural killer cells in cancer immunotherapy..Nat Immunol2016;17:1025-36

[44] Boles KS,Kumaresan PR,Mathew PA.Cloning of a new lectin-like receptor expressed on human NK cells..Immunogenetics1999;50:1-7

[45] Mathew PA,Vaidya SV,Boles KS.The LLT1 receptor induces IFN-gamma production by human natural killer cells..Mol Immunol2004;40:1157-63

[46] Rosen DB,Alsharifi M,Warren HS.Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor..J Immunol2005;175:7796-9

[47] Aldemir H,Dumaurier MJ,Poupon G.Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor..J Immunol2005;175:7791-5

[48] Germain C,Zahn S,Dumaurier MJ.Characterization of alternatively spliced transcript variants of CLEC2D gene..J Biol Chem2010;285:36207-15 PMCID:PMC2975243

[49] Rosen DB,Avery DT,Liu YJ.Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells..J Immunol2008;180:6508-17 PMCID:PMC2577150

[50] Kita S,Kasai Y,Okabe Y.Crystal structure of extracellular domain of human lectin-like transcript 1 (LLT1), the ligand for natural killer receptor-P1A..Eur J Immunol2015;45:1605-13

[51] Skalova T,Harlos K,Koval T.Four crystal structures of human LLT1, a ligand of human NKR-P1, in varied glycosylation and oligomerization states..Acta Crystallogr D Biol Crystallogr2015;71:578-91 PMCID:PMC4356368

[52] Tanaka M,Kirkham CL,Belcheva A.The inhibitory NKR-P1B:Clr-b recognition axis facilitates detection of oncogenic transformation and cancer immunosurveillance..Cancer Res2018;78:3589-603

[53] Iizuka K,Plougastel BF,Yokoyama WM.Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors..Nat Immunol2003;4:801-7

[54] Carlyle JR,Gasser S,Arase H.Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors..Proc Natl Acad Sci U S A2004;101:3527-32 PMCID:PMC373496

[55] Germain C,Jensen T,Poupon G.Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-gamma contributes to modulate immune responses..J Biol Chem2011;286:37964-75 PMCID:PMC3207416

[56] Pasero C,Granjeaud S,Thomassin-Piana J.Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer..Oncotarget2015;6:14360-73 PMCID:PMC4546472

[57] Santos-Juanes J,Lorenzo-Herrero S,Martinez-Camblor P.Lectin-like transcript 1 (LLT1) expression is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma..Arch Dermatol Res2019;311:369-76

[58] Jindal V.Immunotherapy: a glimmer of hope for metastatic prostate cancer..Chin Clin Oncol2018;7:61